ITGA6 and prostate cancer: In the xenograft human prostate cancer mouse model, treatment with the J8H antibody, which blocks ITGA6 by converting it into ITGA6-p, reduces osteolytic tumor activity and induces a sclerotic reaction in bone lesions [18,154].